Evidence map›Paper›PMID 36557244›Full record

ArticleMetabolites2022

An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study.

Rubén Gil-Redondo, Ricardo Conde, Maider Bizkarguenaga, Chiara Bruzzone, Ana Laín, Beatriz González-Valle, Milagros Iriberri, Carlos Ramos-Acosta, Eduardo Anguita, Juan Ignacio Arriaga Lariz and 15 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Recent Trends in Metabolomics by NMR Spectroscopy.Angewandte Chemie (International ed. in English) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 6 countries.

Rubén Gil-RedondoPrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0002-3541-9085
Ricardo CondePrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0003-4372-081X
Maider BizkarguenagaPrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0003-0988-2006
Chiara BruzzonePrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.
Ana LaínPrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0001-7069-9126
Beatriz González-VallePrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0002-7197-3593
Milagros IriberriPneumology Department, Hospital Universitario de Cruces, 48903 Barakaldo, Spain.
Carlos Ramos-AcostaDepartment of Medicine, Faculty of Medicine, UCM, Hematology Department, IML, IdISSC, Hospital Clínico San Carlos, 28040 Madrid, Spain.
Eduardo AnguitaDepartment of Medicine, Faculty of Medicine, UCM, Hematology Department, IML, IdISSC, Hospital Clínico San Carlos, 28040 Madrid, Spain.ORCID 0000-0003-1386-4943
Juan Ignacio Arriaga LarizPneumology Department, Hospital Universitario de Basurto, 48013 Bilbao, Spain.
Pedro Pablo España YandiolaPneumology Department, Hospital Universitario de Galdakao-Usansolo, 48960 Galdakao, Spain.
Miguel Ángel MoranBioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.
Mario Ernesto Jiménez-MercadoBioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.
Leire Egia-MendikuteCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.
María Luisa SecoOSARTEN Kooperatiba Elkartea, 20500 Arrasate-Mondragón, Spain.
Hartmut SchäferBruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.
Claire CannetBruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.
Manfred SpraulBruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.
Asís PalazónCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0002-7172-7229
Nieves EmbadePrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0001-9878-3290
Shelly C LuKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Julien WistAustralian National Phenome Center, and Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia.
Jeremy K NicholsonAustralian National Phenome Center, and Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia.ORCID 0000-0002-8123-8349
José M MatoPrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0003-1264-3153
Oscar MilletPrecision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.ORCID 0000-0001-8748-4105
CIC bioGUNE · ESBruker (Germany) · DEBioCruces Health research Institute · ESHospital Clínico San Carlos · ESInstituto de Salud Carlos III · ESMurdoch University · AUCedars-Sinai Medical Center · USHospital de Basurto · ESHospital de Cruces · ESHospital de Galdakao · ESIkerbasque · ES

Funding

ARC Laureate FellowshipBIOEF EITB Maratoia (BIO21/COV/037)Ministerio de Ciencia, Tecnología e Innovación (Minciencias), Ministerio de Educación Nacional, Ministerio de Industria, Comercio y Turismo e ICETEX (792-2017) 2a Convocatoria Ecosistema Científico - Colombia Científica para la Financiación de ProyeMRFF (grant number 2014349) for funding the Australian National Phenome Centrethe Department of Jobs, Tourism, Science and Innovation, Government of Western Australian Premier's Fellowshipthe European Research Council (ERC) (ERC-2018-StG 804236-NEXTGEN-IO), ISCiii DTS21/00094, RYC2018-024183-I; and PID2019-107956RA-I00The Spinnaker Health Research Foundation, WA, The McCusker Foundation, WA, The Western Australian State Governmentthe SPRI I + D COVID-19 fund (Basque Government, bG-COVID-19)the UK MRCWestern Australian Covid Research Response teamWorld Bank and Vicerrectoría de Investigaciones, Pontificia Universidad Javeriana, Bogotá, Co-lombia (contract no. FP44842 - 221-2018)
6 · The paper itself

Abstract

After SARS-CoV-2 infection, the molecular phenoreversion of the immunological response and its associated metabolic dysregulation are required for a full recovery of the patient. This process is patient-dependent due to the manifold possibilities induced by virus severity, its phylogenic evolution and the vaccination status of the population. We have here investigated the natural history of COVID-19 disease at the molecular level, characterizing the metabolic and immunological phenoreversion over time in large cohorts of hospitalized severe patients (n = 886) and non-hospitalized recovered patients that self-reported having passed the disease (n = 513). Non-hospitalized recovered patients do not show any metabolic fingerprint associated with the disease or immune alterations. Acute patients are characterized by the metabolic and lipidomic dysregulation that accompanies the exacerbated immunological response, resulting in a slow recovery time with a maximum probability of around 62 days. As a manifestation of the heterogeneity in the metabolic phenoreversion, age and severity become factors that modulate their normalization time which, in turn, correlates with changes in the atherogenesis-associated chemokine MCP-1. Our results are consistent with a model where the slow metabolic normalization in acute patients results in enhanced atherosclerotic risk, in line with the recent observation of an elevated number of cardiovascular episodes found in post-COVID-19 cohorts.

Indexed as

atherosclerotic riskCOVID-19inflammationlipidomicslong COVIDmetabolomics

Identifiers

PMID36557244
PMCPMC9788519
OpenAlexW4311161409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.